secwatch.observer — SEC 8-K summary
======================================

Issuer:     SKINVISIBLE, INC. (SKVI)
CIK:        0001085277
Form:       8-K
Filed at:   2024-05-29T23:59:59+00:00
Accession:  0001663577-24-000143
Event type: other_material
Sentiment:  positive
Materiality: 0.30
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skinvisible files provisional patent for transdermal obesity drug delivery using Invisicare
--------------------------------------------------------------------------------

- Provisional patent filed for transdermal composition of CB-1 receptor antagonists and/or GLP-1 receptor agonists.
- Uses proprietary Invisicare technology; studies show up to 10x increase in transdermal delivery effectiveness.
- Aims to offer needle-free alternative to injections for obesity drugs; potential to improve compliance.
- Global obesity drug market projected to exceed $30B by 2027.
- Company actively seeking strategic partnerships for development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1085277/000166357724000143/0001663577-24-000143-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1085277/000166357724000143/skvi8k052924.htm
  HTML page:      https://secwatch.observer/filing/0001663577-24-000143

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer